Venozās trombembolijas rekurence Latvijas populācijā - universitātes slimnīcas dati.
No Thumbnail Available
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Venozā trombembolija (VTE), kurā ietilpst dziļo vēnu tromboze (DVT) un plaušu embolija (PE), ir trešais biežākais nāves cēlonis no sirds un asinsvadu slimībām, uzreiz pēc akūta miokarda infarkta un insulta. VTE atkārtošanās pēc primārā notikuma ir izplatīta, un tās kopējais sastopamības biežums ir 4,9 gadījumi uz 100 pacientiem. VTE atkārtošanās risku ietekmē vīriešu dzimums, ķermeņa masas indekss, etniskā izcelsme, zemāks sociālekonomiskais līmenis statuss, trombofīlija, hormonālā terapija, grūtniecība un vēzis.
Ir izstrādāti vairāki VTE riska rādītāji, piemēram, HERDOO2 rādītājs, Vīnes prognozēšanas modelis, DASH rādītājs, bet neviens no tiem vēl nav iekļauts starptautiskajās vadlīnijās.
Šī pētījuma mērķis bija novērtēt iespējamo klīnisko risku atkārtotai VTE, ieskaitot blakusslimības, vēzi, VTE provocējošos faktorus, laboratorijas datus un ārstēšanas metodes.
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of death from cardiovascular disease after acute myocardial infarction and stroke. Recurrence of VTE after a primary event is common with an overall incidence rate of 4.9 per 100 person-years in non-cancer patients. Higher recurrence risk has been associated with an “unprovoked” primary VTE events and malignancy-related VTE with a 1-year risk of approximately 10% and 15%, respectively. Previously described demographic and clinical risk factors for recurrence are male gender, body-mass index, ethnic background, lower socioeconomic status, thrombophilia, hormonal therapy, pregnancy, and cancer, among others. Several multivariate risk scores such as HERDOO2 score, Vienna prediction model, DASH score have been developed but due to the lack of sucient external validation, none of them have yet been included in international guidelines. Recent studies have demonstrated the superiority of long-term direct oral anticoagulants (DOAC) over vitamin K antagonists (VKA) and low-molecular-weight heparins (LMWH) in preventing recurrent VTE. The aim of this study was to assess the possible clinical risk factors for VTE recurrences, including comorbidities, cancer, VTE provoking factors, demographic features, laboratory data, and treatment approaches.
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of death from cardiovascular disease after acute myocardial infarction and stroke. Recurrence of VTE after a primary event is common with an overall incidence rate of 4.9 per 100 person-years in non-cancer patients. Higher recurrence risk has been associated with an “unprovoked” primary VTE events and malignancy-related VTE with a 1-year risk of approximately 10% and 15%, respectively. Previously described demographic and clinical risk factors for recurrence are male gender, body-mass index, ethnic background, lower socioeconomic status, thrombophilia, hormonal therapy, pregnancy, and cancer, among others. Several multivariate risk scores such as HERDOO2 score, Vienna prediction model, DASH score have been developed but due to the lack of sucient external validation, none of them have yet been included in international guidelines. Recent studies have demonstrated the superiority of long-term direct oral anticoagulants (DOAC) over vitamin K antagonists (VKA) and low-molecular-weight heparins (LMWH) in preventing recurrent VTE. The aim of this study was to assess the possible clinical risk factors for VTE recurrences, including comorbidities, cancer, VTE provoking factors, demographic features, laboratory data, and treatment approaches.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
Venozā trombembolija, Venous thromboembolism